[A18-25] Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V
Last updated 04.10.2018
Project no.:
A18-25
Commission:
Commission awarded on 13.04.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Mental and emotional wellbeing
Adults with schizophrenia
Long-term treatment: In patients with mostly negative symptoms hint of a non-quantifiable added benefit. Remaining patients as well as acute treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-50 | Cariprazine (schizophrenia) - Addendum to Commission A18-25 | Commission completed |
Federal Joint Committee (G-BA)
2018-10-04 A G-BA decision was published.